PMID- 36267618 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221022 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 9 DP - 2022 TI - The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study. PG - 918468 LID - 10.3389/fmed.2022.918468 [doi] LID - 918468 AB - BACKGROUND: Oxycodone hydrochloride is a semisynthetic narcotic analgesic agent. This study aimed to explore optimal titration strategy of controlled-release (CR) oxycodone hydrochloride in patients with cancer pain. METHODS: 258 patients, who used regular strong opioids (morphine and CR oxycodone hydrochloride) for cancer pain across 25 three grade class hospitals in China during January 15th 2017 to April 30th 2017, were retrospectively studied. The patients were divided into 4 groups according to treatment regimens titrated. The pain remission rate and numeric rating scale (NRS) of cancer pain was recorded at 0, 12, 24, 36, 48, 60, 72 h after opioid titration. The incidence of adverse events (AEs) with therapy were also observed. RESULTS: 12 h after treatment, pain remission rate of Group B, C and D was significantly higher (P < 0.001) than Group A. For the complete remission rate, there were also significant differences among the four groups (P < 0.001). No significant difference was found among four groups for pain remission rate at 24, 72 h after treatment. Multiple comparison of NRS scores showed that the both Group B and C varied significantly with Group D (P = 0.028, P = 0.05, respectively), showing superior analgesic effect over Group D. AEs were significantly different among groups (P < 0.01), with the most frequent AEs in Group A, lowest in Group B. CONCLUSION: The rapid titration strategy of background CR oxycodone hydrochloride was effectiveness and safety in patients with moderate-to-severe cancer pain. CI - Copyright (c) 2022 Feng, Wang, Ran, Mao, Zhang, Wang, Lin, Wang, Hu, Liao, Zhang, Chu, Xiong, Yi, Yi, Ma, Sun, Meng, Liu, Zhou, Zheng, Wang, Lin, Fang, Li and Wu. FAU - Feng, Weineng AU - Feng W AD - Department of Head and Neck/Thoracic Medical Oncology, The First People's Hospital of Foshan, Foshan, China. FAU - Wang, Yufeng AU - Wang Y AD - Department of Cadre Medical Section, Yunnan Cancer Hospital & the Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, China. FAU - Ran, Fengming AU - Ran F AD - Department of Oncology, Hubei Cancer Hospital, Wuhan, China. FAU - Mao, Yong AU - Mao Y AD - Department of Pain Management, Yunnan Cancer Hospital & the Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, China. FAU - Zhang, Helong AU - Zhang H AD - Department of Oncology, Tangdu Hospital of Air Force Medical University, Xi'an, China. FAU - Wang, Qifeng AU - Wang Q AD - Department of Thoracic Radiotherapy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Cancer Hospital Affiliate to School of Medicine, UESTC, Chengdu, China. FAU - Lin, Wen AU - Lin W AD - Department of Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China. FAU - Wang, Zhidong AU - Wang Z AD - Department of Oncology, Changsha Hospital of Traditional Chinese Medicine (Changsha Eighth Hospital), Changsha, China. FAU - Hu, Jianli AU - Hu J AD - Cancer Center, Xiehe Hosptial Tongji Medical College Huazhong University of Science and Technology, Wuhan, China. FAU - Liao, Wangjun AU - Liao W AD - Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Zhang, Tao AU - Zhang T AD - Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Chu, Qian AU - Chu Q AD - Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Shanghai, China. FAU - Xiong, Weijie AU - Xiong W AD - Department of Oncology, Chengdu Fifth People's Hospital, Chengdu, China. FAU - Yi, Tienan AU - Yi T AD - Department of Oncology, The Central Hospital of Xiangyang, Chengdu, China. FAU - Yi, Jiqun AU - Yi J AD - Department of Oncology, Guangzhou Red Cross Hospital, Guangzhou, China. FAU - Ma, Shoucheng AU - Ma S AD - Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, China. FAU - Sun, Yi AU - Sun Y AD - Department of Hematology and Oncology, Hospital 452 of PLA, Chengdu, China. FAU - Meng, Lingzhan AU - Meng L AD - Department of Oncology, Chongqing Traditional Chinese Medicine Hospitai & No. 4 Clinical Medicine School of Chengdu University of TCM, Chongqing, China. FAU - Liu, Chunling AU - Liu C AD - Respiratory Department, Xinjiang Cancer Hospital, Urumqi, China. FAU - Zhou, Silang AU - Zhou S AD - Department of Oncology, PLA Army 74 Group Army Hospital, Guangzhou, China. FAU - Zheng, Dengyun AU - Zheng D AD - Department of Oncology, Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. FAU - Wang, Shubin AU - Wang S AD - Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China. FAU - Lin, Haifeng AU - Lin H AD - Department of Oncology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China. FAU - Fang, Wenzheng AU - Fang W AD - Department of Oncology, Fuzhou PLA General Hospital, Fuzhou, China. FAU - Li, Jun AU - Li J AD - Department of Oncology, The Central Hospital of Wuhan, Wuhan, China. FAU - Wu, Minhui AU - Wu M AD - Department of Integrated Chinese and Western Medicine, Shaanxi Cancer Hospital Affiliated to Medical College of Xi'an Jiaotong University, Xi'an, China. LA - eng PT - Journal Article DEP - 20221004 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC9576945 OTO - NOTNLM OT - cancer pain OT - controlled-release (CR) oxycodone OT - dose titration OT - immediate-release (IR) morphine OT - oxycodone hydrochloride OT - pain remission COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/22 06:00 MHDA- 2022/10/22 06:01 PMCR- 2022/10/04 CRDT- 2022/10/21 02:57 PHST- 2022/04/12 00:00 [received] PHST- 2022/09/14 00:00 [accepted] PHST- 2022/10/21 02:57 [entrez] PHST- 2022/10/22 06:00 [pubmed] PHST- 2022/10/22 06:01 [medline] PHST- 2022/10/04 00:00 [pmc-release] AID - 10.3389/fmed.2022.918468 [doi] PST - epublish SO - Front Med (Lausanne). 2022 Oct 4;9:918468. doi: 10.3389/fmed.2022.918468. eCollection 2022.